Involvement and therapeutic applications of the fibrinolytic system in bronchial asthma

• Project/Area Number: 24790824
• Research Category: Grant-in-Aid for Young Scientists (B)
• Allocation Type: Multi-year Fund
• Research Field: Respiratory organ internal medicine
• Research Institution: Keio University
• Principal Investigator: TSUZUKI Keishi 慶應義塾大学, 医学部, 研究員 (50445277)
• Project Period (FY): 2012-04-01 – 2015-03-31
• Project Status: Completed (Fiscal Year 2014)
• Budget Amount: ¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000); Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000); Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000); Fiscal Year 2012: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
• Keywords: 気管支喘息 / uPA / PAI-2

Outline of Final Research Achievements

PAI-2 is regarded as the target molecule of new asthma treatment, that is different from the fibrinolysis inhibiting activity. We have examined the possibility of asthma treatment with urokinase(uPA) as a ligand of PAI-2. In airway epithelial cell model, good results of asthma related mediators such as Eotaxin, RANTES, Eotaxin-3 in the stimulation with IL-4 and TNFα is suppressed expression in uPA concentration dependence was obtained.